AlphaStocks
5.3
Consider Buy

Roivant Sciences Ltd. (ROIV)

As of Sep 20, 2026, Roivant Sciences Ltd. (ROIV) scores 5.3/10 on AlphaStocks' five-model composite, #97 of 168 Health Care stocks.

Health Care / Biotechnology

S&P MidCap 400

$39.81

Below average on several measures. Research carefully.

Consider Buy

Score based on 3 of 5 models — moderate confidence

Data as of Sep 20, 2026

#97out of 168 in Health Care

Is Roivant Sciences Ltd. a Good Investment in 2026?

Roivant Sciences Ltd. (ROIV) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model is the most favorable, rating Roivant Sciences Ltd. as Neutral. However, the Graham model rates it Caution. Roivant Sciences Ltd. ranks #97 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-6.8Market Cap28B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Caution

2/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Roivant Sciences Ltd. (ROIV) a good investment?
As of Sep 20, 2026, Roivant Sciences Ltd. (ROIV) scores 5.3/10 on AlphaStocks' five-model composite, #97 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Roivant Sciences Ltd.'s Piotroski F-Score?
Roivant Sciences Ltd.'s Piotroski F-Score status is Caution. The raw score is 2/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ROIV overvalued or undervalued?
A precise fair value estimate is not available for ROIV. Currently unprofitable — fair value estimate not available.
How does ROIV compare to other Health Care stocks?
Roivant Sciences Ltd. ranks #97 out of 168 stocks in the Health Care sector, placing it in the top 58% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ROIV?
AlphaStocks evaluates ROIV using five proven investment models. Piotroski: Caution; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

ABBVINCYHRMY

Compare ROIV with

ABBV vs ROIVINCY vs ROIVHRMY vs ROIV

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer